Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients.
Bryn
Tone
T
Mahic
Milada
M
Aandahl
Einar M
EM
Frøland
Stig S
SS
Aukrust
Pål
P
Taskén
Kjetil
K
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002478:Cells, Cultured; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000378:metabolism; D015232:Dinoprostone / Q000494:pharmacology*; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D020889:Rolipram / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D019380:Anti-HIV Agents; D008070:Lipopolysaccharides; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D017868:Cyclic AMP-Dependent Protein Kinases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C517360:PDE4B protein, human; D020889:Rolipram; D015232:Dinoprostone; D015056:1-Methyl-3-isobutylxanthine